Lilly’s Glyxambi Is First SGLT2/DPP-4 Combo Product For Diabetes
This article was originally published in The Pink Sheet Daily
Glyxambi is the latest in a series of new diabetes drugs for Eli Lilly, following on the heels of Jardiance and Trulicity. The company highlighted new drugs and its pipeline during its year-end financial call.
You may also be interested in...
The company launched three diabetes drugs in 2014, just after breaking off a joint venture with Bristol-Myers and taking over full control of the business. U.S. President Paul Hudson talked about the evolution of AstraZeneca’s diabetes business – and where it stands today – in a recent interview.
Eli Lilly has signed on as a risk-sharing partner with AstraZeneca to develop a BACE inhibitor for Alzheimer’s disease. The deal gives Lilly a mid-stage asset in the challenging field after two of its own candidates failed in late-stage trials.
While questions about the company’s internal reorganization dominated its second-quarter earnings call, Pfizer management also provided some clinical and pipeline updates. Pfizer said the partial clinical hold on its anti-nerve growth factor tanezumab has been lifted and it is preparing to begin Phase III clinical trials in 2014.